Lotilaner Ophthalmic Solution 0.25%: First Approval.
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
medline:
6
11
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
ppublish
Résumé
Lotilaner ophthalmic solution 0.25% (XDEMVY™), a gamma-aminobutyric acid-gated chloride channel (GABA-Cl) inhibitor selective for mites, is being developed by Tarsus Pharmaceuticals for the treatment of Demodex blepharitis and meibomian gland dysfunction in patients with Demodex lid infestation (Demodex-induced meibomianitis). On 24 July 2023, lotilaner ophthalmic solution 0.25% received its first approval in the USA for the treatment of Demodex blepharitis. The agent is also currently in phase 3 development for Demodex blepharitis in China and phase 2 development for Demodex-induced meibomianitis in the USA. This article summarizes the milestones in the development of lotilaner ophthalmic solution 0.25% leading to this first approval for the treatment of Demodex blepharitis in the USA.
Identifiants
pubmed: 37843754
doi: 10.1007/s40265-023-01947-9
pii: 10.1007/s40265-023-01947-9
pmc: PMC10624734
doi:
Substances chimiques
lotilaner
0
Ophthalmic Solutions
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1537-1541Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. Springer Nature.
Références
J Ocul Pharmacol Ther. 2021 Oct;37(8):479-484
pubmed: 34415795
Eye Contact Lens. 2023 Aug 1;49(8):311-318
pubmed: 37272680
Cornea. 2023 Apr 1;42(4):435-443
pubmed: 35965392
Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3089-94
pubmed: 16123406
Biochem Biophys Res Commun. 2010 Jan 1;391(1):744-9
pubmed: 19944072
Clin Optom (Auckl). 2018 Jul 04;10:57-63
pubmed: 30214343
Cont Lens Anterior Eye. 2022 Aug;45(4):101492
pubmed: 34332895
J Ophthalmol. 2021 Sep 21;2021:3862684
pubmed: 34603770
Ocul Immunol Inflamm. 2023 Oct;31(8):1653-1661
pubmed: 35914297
Ophthalmology. 2023 Oct;130(10):1015-1023
pubmed: 37285925
J Vet Pharmacol Ther. 2022 Jan;45(1):1-15
pubmed: 33733534
Clin Ophthalmol. 2023 Feb 27;17:667-679
pubmed: 36875531